TRPS1 expression in neuroendocrine neoplasms of breast and other organs
- 30 September 2025
- journal article
- Published by Wiley in Histopathology
- Vol. 88 (2) , 524-532
Abstract
Background: Primary neuroendocrine (NE) neoplasms of the breast are rare. In the absence of in situ carcinoma, metastasis from other organs needs to be ruled out first. TRPS1 is a recently identified marker for breast origin. In the current study, we investigated TRPS1 expression in breast neuroendocrine neoplasms, including well‐differentiated neuroendocrine tumour (NET) and poorly differentiated neuroendocrine carcinoma (NEC), and compared its expression with neuroendocrine neoplasms from other organs, such as lung, gastrointestinal tract and pancreas. Methods and results: A total of 105 cases of NE neoplasms were included in our study cohort, including 56 from breast (39 NETs and 17 NECs), 18 from lung (12 typical and atypical carcinoids, and 6 NECs), 19 from gastrointestinal tract (10 NETs, 3 NECs, 6 NETs metastases to breast) and 12 from pancreas (9 NETs, 3 NECs). TRPS1 exhibited moderate to strong expression in 38 of 39 breast NETs (97.4%). Four of 17 (23.5%) breast NECs showed weak to moderate staining. By contrast, no TRPS1 staining was observed in any of the 18 lung and 12 pancreatic NE neoplasms. Among 19 gastrointestinal NE neoplasms, only 1 NEC displayed scattered low TRPS1 positivity. Conclusions: Our study demonstrated that TRPS1 is universally expressed in mammary NET, and it is a valuable marker to distinguish primary mammary NET from metastatic NET of other organs, including lung, gastrointestinal tract and pancreas. TRPS1 has limited utility in differentiating mammary NEC from NEC of other organs. Clinical radiographic correlation is paramount in diagnosing primary NEC of the breast.Keywords
This publication has 57 references indexed in Scilit:
- Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcomeVirchows Archiv, 2022
- The classification of neuroendocrine neoplasms of the breast and its clinical relevanceVirchows Archiv, 2021
- An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomasVirchows Archiv, 2021
- The genetic landscape of breast carcinomas with neuroendocrine differentiationThe Journal of Pathology, 2016
- Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breastBreast Cancer Research and Treatment, 2014
- Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers?Journal of Surgical Oncology, 2011
- Late manifestations of tricho‐rhino‐pharangeal syndrome in a patient: Expanded skeletal phenotype in adulthoodAmerican Journal of Medical Genetics Part A, 2010
- Small cell neuroendocrine (Oat cell) carcinoma of the breastCancer, 2006
- CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumorsVirchows Archiv, 2004
- Carcinomas of the breast with endocrine differentiation: a reviewVirchows Archiv, 1994